Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
GENEVA, SWITZERLAND / ACCESSWIRE / April 7, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat COVID-19 induced respiratory disorder...
NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir PR Newswire RADNOR, Pa. , April 6, 2021 /PRNewswire/ -- NeuroRx, Inc. reports today that Aviptadil, to be...
60-day results have been presented by Relief's partner, NeuroRx, Inc. GENEVA, SWITZERLAND / ACCESSWIRE / March 30, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical d...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthier Choices Management (OTCMKTS: HCMC ) stock is getting a lot of interest from investors today as the company relaunches its vitamins and supplements online store. Source: Saowanee K/Shutterstock.com Acco...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning and welcome to the stock market today! The Ever Given is free , Wall Street is caught up in a fire sale tizzy and cryptos are climbing again. So what will the stock market do today? And what do you need to kno...
/C O R R E C T I O N -- NeuroRx/ PR Newswire In the news release, NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b /3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19, issued ...
NeuroRx and Relief Therapeutics (RLFTF) report 60-day results of the Phase 2b/3 trial of intravenously-administered Zyesami (aviptadil acetate) for the treatment of respiratory failure due to COVID-19.Zyesami met the primary endpoint for successful recovery from respiratory failure at days 28...
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 PR Newswire RADNOR, Pa. , March 29, 2021 /PRNewswire/ -- NeuroRx, I...
Some Of The Best Penny Stocks To Watch Early This Week This week has started stronger than the last & we have plenty of trending penny stocks to watch as a result. Last week the markets sold off, with tech continuing its move lower. What’s more, over the weekend, new virus da...
RELIEF THERAPEUTICS Holding (RLFTF) and Acer Therapeutics (ACER) have entered into a Collaboration and License Agreement (“CLA”) for worldwide development and commercialization of ACER-001, a proprietary powder formulation of sodium phenylbutyrate ((NaPB)) designed to be both ta...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
Mondobiotech Holding AG Basel Website:
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, ann...
GENEVA, SWITZARLAND / ACCESSWIRE / May 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Mee...
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its ne...